Skip to content

Loading Events

« All Events

  • This event has passed.

New Technologies To Maximize Surgical Outcomes

March 18, 2021 @ 7:30 pm - 9:00 pm

New Technologies To Maximize Surgical Outcomes

  • WHEN

    Thursday, March 18
    7:30 - 9:00PM





Join Surgical Field Product Specialist, Yeabsera Tamire, who will be presenting the Surgical and Sports Medicine Portfolio focusing on Foot and Ankle applications.

Products to be discussed are as follows:

  • NuCel- Cryopreserved Amniotic Suspension Allograft for OR Site of Service
  • Renu- Cryopreserved Amniotic Suspension Allograft for Private Office Site of Service
  • Nushield- Complete Dehydrated Placental Allograft for OR, Private Office and Ambulatory Surgical Sites of Service
  • FiberOS- Blend of demineralized cortical fibers, mineralized cortical powder, and demineralized cortical powder, all derived from the same donor, with natural osteoconductive and osteoinductive properties.
  • OCMP- Blend of ground cancellous chips and demineralized cortical powder, derived from the same donor, with natural osteoconductive and osteoinductive properties
  • Puraply AM- Collagen and PHMB Antimicrobial indicated for the management of surgical wounds
  • Puraforce Tendon Reinforcement Matrix- Native Porcine ECM used to add support and reinforcement to tendon and soft tissue repairs


Yeabsera Tamire is a Field Product Specialist with Organogenesis. She has a degree in Biochemistry and Molecular Biology from University of Maryland, Baltimore County. She is a published author, with 7 years of experience in the field of regenerative medicine. Currently, Yeabsera bridges the gap between scientists, physicians, and surgeons by engaging in roles that allow dissemination of preclinical and clinical research about novel, cutting-edge biologics and allograft solutions, with the aim to translate biomedical research to directly help


Organogenesis was founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). Our long and successful history of empowering healing began with the introduction of Apligraf®, the first and still the only living cell-based product that is FDA approved to treat both diabetic foot ulcers and venous leg ulcers. In 2014, our product portfolio expanded to include Dermagraft®, an FDA-approved therapy for the treatment of diabetic foot ulcers. The launch of our PuraPly® product line in 2015 gave clinicians new options for wound management across a variety of acute and chronic wound types. The introduction of PuraPly® Antimicrobial as an advanced wound care product has also addressed the growing need to manage bioburden and prevent biofilm reformation. In 2017, Organogenesis acquired NuTech Medical, which further expanded our product portfolio and introduced additional solutions for the advanced wound care market and enabled us to enter the surgical and sports medicine markets in a meaningful way.


March 18, 2021
7:30 pm - 9:00 pm



Why ENFD Analysis Provides the Best Tool to Confirm Small Fiber Peripheral Neuropathy

December 20, 2022

One quick in-office procedure can provide a definitive diagnosis, allowing for effective treatment and symptom relief Have patients complained of burning pain, tingling, numbness, or a pins and needles feeling…

Accurate diagnostic method for web space infectious dermatitis

July 19, 2022

Article sponsored by bakodx. A new web space PCR test can be used as the first line diagnostic option for patients with superficial web space dermatitis to diagnose or rule…

Scroll To Top